The company''s medicines received over 10 regulatory approvals in Europe, Japan, and the US in the first half of 2022. Read more to see our price target on BMY.
→ Google Traductor
Pfizer, Inc. with ticker code (PFE) now have 20 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 75 and 44 with the average target price sitting at 56.81. Now with the previous closing price of 43.83 this is indicating there is a potential upside of 29.6%. The day 50 moving average is 48.21 and the 200 day MA is 51.18. The market capitalisation for the company is $247,449m. You can visit the company''s website by visiting: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $320,729m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
Bristol-Myers Squibb Company (NYSE:BMY) price closed higher on Tuesday, September 27, jumping 0.30% above its previous close. A look at the daily price movement shows that the last close reads $70.15, with intraday deals fluctuated between $70.195 and $71.495. The company’s 5Y monthly beta was ticking 0.42 while its P/E ratio in the trailing 12-month … If You’re Not Bullish On Bristol-Myers Squibb Company (NYSE: BMY) Now, You’ll Kick Yourself Later Read More »
→ Google Traductor
Tuesday''s top analyst upgrades and downgrades included Bristol-Myers Squibb, Costco Wholesale, Dollar General, Exxon Mobil, FedEx, Horizon Therapeutics, Hyatt Hotels, Lucid, Medtronic, Micron Technology, Salesforce, Six Flags Entertainment, Tellurian and Unity Software.
→ Google Traductor
NORTHAMPTON / ACCESSWIRE / September 26, 2022 / Bristol Myers Squibb Company: At Bristol Myers Squibb, Global Patient Week stands as a pinnacle of our year-round vision to transform patients'' lives through science, bringing together our more than 32,000 employees around the world to celebrate the individuals we work each day to serve. This year, in collaboration with the patient advocacy groups we partner with, we asked a few of our Leadership Team members to share their perspectives on how the work their teams are leading impacts lives around the world. Medical knowledge keeps accelerating exponentially, according to a widely cited study from the National Institutes of Health. In 1950, medical knowledge was estimated to double every 50 years. But by 1980 it doubled every seven years, and by 2010, every 3.5 years. By 2020 the collective universe of medical knowledge - all the available information accumulated across time about diseases and therapies; in short, everything we know about our patients - was projected to double every 73 days.
→ Google Traductor
Pfizer found using ticker (PFE) have now 20 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 75 and 44 calculating the mean target price we have 56.81. Now with the previous closing price of 44.57 this would imply there is a potential upside of 27.5%. The 50 day moving average now sits at 48.37 and the 200 day moving average is 51.22. The market cap for the company is $247,392m. You can visit the company''s website by visiting: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $315,332m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Click to read.
→ Google Traductor
The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. Nu Skin Enterprises The Trade: Nu Skin Enterprises, Inc. (NYSE: NUS ) Director Andrew D Lipman sold a total of 1,000 shares at an average price of $36.67. The insider … Full story available on Benzinga.com
→ Google Traductor
On CNBC’s “ Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY ) has a “good dividend yield” and is a “cheap stock in a defensive industry.” “I think this is an easy one to buy no matter what you … Full story available on Benzinga.com
→ Google Traductor
The big pharma stock continues to trounce the major market indexes so far this year.
→ Google Traductor
Following strong rallies that defied the broader stock market, corporate insiders at defensive pharmaceutical companies Catalyst Pharmaceuticals (NASDAQ:CPRX) and Bristol-Myers Squibb Company (NYSE:BMY) have been selling their employers'' stock in large numbers so far this month. While insider selling is not necessarily a Sell signal, it''s something worth noting. This is because corporate insiders have a deeper knowledge of a company''s business and can foresee changes in its operating environment way ahead of the general investing public. The TipRanks Insider Trading tool has identified recent SEC filings by corporate insiders in the two pharma stocks mentioned above and deemed them "informative.
→ Google Traductor
The idea that anyone could have a problem with Joe Biden’s cancer moonshot is unimaginable. After all, who hasn’t had a friend or relative affected by cancer? My dad died from a combination of prostate and bone cancer. Now, you could argue that, at 81, old age might have done him in, regardless of the disease eating away at his body. But, the reality is that so many die much younger than my dad from various forms of cancer. It is a scourge to longevity everywhere. Biden’s cancer moonshot aims to cuts the death rate from cancer in the U.S. by 50% over the next 25 years while improving the experience of those dealing with cancer. I’m 100% for it. I’m sure the drug companies are, too. Forget the old myth that they don’t want to cure cancer. There is a lot of money to be made by eliminating a virus or disease. Who are the companies developing the best cancer moonshots? Below are three possibilities. MRK Merck & Co $86.02 NVS Novartis $79.58 LLY Eli Lilly $301.69 Merck & Co. (MRK) Source: Atmosphere1 / Shutterstock.com Merck & Co. (NYSE: MRK ) reported better-than-expected Q2 revenue and profits thanks to Keytruda , the company’s cancer drug that binds to the PD-1 protein, helping immune cells kill cancer cells.
→ Google Traductor
New Jersey, USA -- ( SBWIRE ) -- 09/19/2022 -- Advance Market Analytics published a new research publication on "Bio-pharmaceuticals Market Insights, to 2027" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Bio-pharmaceuticals market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/104952-global-bio-pharmaceuticals-market#utm_source=SBWireLal The Bio-pharmaceuticals Market report covers extensive analysis of the key market players, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Pfizer (United States), F. Hoffmann-La Roche AG (Switzerland), AbbVie(United States), Johnson& Johnson (United States), Sanofi (France), AstraZeneca (United Kingdom), Novartis (Switzerland), Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Bristol-Myers Squibb Company (United States), Cadila Healthcare Limited (Zydus Cadila) (India), Amgen (United States), Abbott Laboratories (United States), Biocon Ltd (India).
→ Google Traductor
Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become. That means that penny stocks, which are riskier by nature, are finding their ratings declining in the current environment. A few months ago penny stocks with buy ratings that were doing well suddenly found themselves downgraded to a hold rating or worse. That indicates that the already risky world of penny stocks is becoming riskier still. So, it should come as little surprise that investors are seeking penny stocks with buy ratings through early September. Those equities should have more stability and better chances of price appreciation in what is usually a tough month for equities. That said, let’s dive deeper into those shares. NNDM Nano Dimension $2.50 HYRE HyreCar $1.28 MNKD MannKind $3.56 TBLT ToughBuilt Industries $2.37 AGEN Agenus $2.36 NBEV NewAge $0.09 CORZ Core Scientific $1.90 Nano Dimension (NNDM) Source: Spyro the Dragon / Shutterstock.com Nano Dimension (NASDAQ: NNDM ) stock carries a buy rating and plenty of upside.
→ Google Traductor
Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.
→ Google Traductor
(Reuters) – Drugmakers Bristol Myers Squibb Co and AbbVie Inc told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week.
→ Google Traductor
Gold futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. Newell Brands The Trade: Newell Brands Inc. (NASDAQ: NWL ) Director Brett … Full story available on Benzinga.com
→ Google Traductor
Investors were cheered by good news from the lab.
→ Google Traductor
When compiling my small-cap stock picks, I tried to choose names that seemed to be benefiting from this new, more “risk-on” environment. Among the encouraging features of the August Consumer Price Index report were the 0.1% month-over-month increase in the headline number and the deceleration of the year-over-year CPI to 8.3% from 8.5% in July, Additionally, the increase in the labor participation rate last month should put downward pressure on wages. Professor Jeremy Siegel along with a growing list of experts , expects inflation to naturally ease in the longer term which is good news for peeople seeking the best small-cap stock picks. Finally, the Russell 2000 , an index of small-cap stocks, surged from 1,791 on Sept. 6 to 1,906 on Sept. 12. These small-cap stock picks take into account much of the breaking news and assume investors don’t mind some risk. MTBC CareCloud $4.67 CAAP Corporación América Airports $7.07 DHT DHT $8.84 VLDR Velodyne Lidar $1.22 LOCO El Pollo Loco $9.00 EMBK Embark $10.71 SDGR Schrodinger $28.96 Carecloud ( MTBC ) Source: Supavadee butradee / Shutterstock.com CareCloud (NASDAQ: MTBC ) markets a variety of software to healthcare companies.
→ Google Traductor
Bristol Myers Squibb (NYSE:BMY) declares $0.54/share quarterly dividend, in line with previous.Forward yield 3.07%Payable Nov. 1; for shareholders of record Oct. 7; ex-div Oct.
→ Google Traductor
The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.
→ Google Traductor
Wednesday''s additional top analyst upgrades and downgrades were on Block, Bristol-Myers Squibb, Clorox, CSX, Kimberly-Clark, Merck, Match, Target and more.
→ Google Traductor
Amgen (AMGN) shares reached the lowest level since March as Wall Street reacted to the company''s latest update on KRAS inhibitor Lumakras, while Bristol Myers (BMY) introduced a new…
→ Google Traductor
Clinical-stage biopharmaceutical company Ventyx Biosciences saw its shares skyrocket to a new 52-week high of $41.29 after peer Bristol Myers Squibb’s (NYSE:BMY) Sotyktu was approved by the U.S. Food and Drug Administration (FDA). Notably, Sotyktu (deucravacitinib), which is used for the treatment of plaque psoriasis, was approved by the FDA without any black-box warning. This means that the drug does not come under the purview of carrying serious safety risks and foretells a relatively easier entry into the market for other competitive drug makers.
→ Google Traductor
Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer. Euphoria gave way to a market slump. Markets reversed their mood when the Federal Reserve reiterated a tough stance during the annual meeting at Jackson Hole . The September slump created seven screaming picks to beat the market for investors. AAPL Apple $163.43 BMY Bristol-Myers Squibb $72.36 FDX FedEx $213.84 INTC Intel $31.56 MA Mastercard $338.42 MMM 3M $124.25 VTRS Viatris $10.11 Apple (AAPL) Source: sylv1rob1 / Shutterstock.com Apple’s (NASDAQ: AAPL ) long-awaited product iPhone 14 and iPhone 14 Plus refresh assures continued revenue strength. Most importantly, the smartphone giant did not raise the price of the models. The iPhon14 will start at $799 while the 14 Pro will start at $999. This is one of the reasons AAPL is among the top stock picks to beat the market. Apple also introduced three levels of Apple Watch.
→ Google Traductor
Stocks that traded heavily or had substantial price changes Monday: Bristol-Myers, Gilead rise, SVB Financial, BioMarin fall
→ Google Traductor
The stock market''s recent rally continued Monday, with the major market indexes closing today at their highest levels since late August. The gains came ahead of tomorrow morning''s release of the August consumer price index (CPI) – the last key piece of economic data for the Federal Reserve to consider ahead of its policy meeting next week. "The U.S. consumer price index, to be released on Tuesday, will likely show that August prices rose at an 8.1% pace over the year, compared to the July print at 8.5%," says Jon Maier, chief investment officer at Global X ETFs. "If this number comes to pass, it will show that inflation is slowing some, albeit from very high levels." SEE MORE Playing Favorites: 5 Top Stocks for Inflation However, even with better CPI numbers, the Federal Reserve is likely "to continue on its path for another 75 basis-point hike later this month," Maier adds. "The Fed is in a tough spot because employment reports suggest labor demand and employment growth have not slowed that much due to Fed actions thus far." Investor sentiment was also boosted by reports of Ukraine''s successful counteroffensive against Russian troops in the country''s northeastern Kharkiv region. "The start of the trading week was supposed to be all about the August inflation report, but Kyiv''s sudden momentum has many hoping that this moment is a turning point with the war against Russia," says Edward Moya, senior market strategist at currency data provider OANDA.
→ Google Traductor
Stocks rose on Monday as a weaker dollar and growing confidence that inflation has peaked helped Wall Street’s relief rally continue ahead of key inflation report. The Dow Jones Industrials raced 229.63 points to conclude Monday at 32,381.34 The S&P 500 tacked 43.05 points, or 1.1%, to 4,110.41. The NASDAQ Composite jumped 154.10 points, or 1.3%, to 12,266.41. Energy was the top sector, but the rally was broad, with Bristol-Myers Squibb gaining nearly 6% and tech stalwart Apple adding 3.4%. The moves extended a rebound for U.S. stocks, as all three major averages snapped a three-week losing streak on Friday. Stocks have been volatile ahead of the September 20-21 meeting of the Federal Reserve, where the central bank is expected to deliver its third consecutive 0.75-percentage-point rate hike in an effort to combat high inflation. Wall Street investors have been looking for signs that future rate hikes might be smaller as inflation cools off, but Fed Chair Jerome Powell last week reiterate Treasury prices retreated Monday, raising yields to 3.35% from Friday’s 3.32%.
→ Google Traductor
Source: Savvapanf Photo/ShutterStock.com Restaurant Brands International (NYSE: QSR ) stock is gaining on Monday after Burger King announced plans to invest $400 million into its business . According to the fast food chain, it will use these funds to upgrade its facilities. That includes enhancing equipment used by its employees, as well as remodeling select stores with a more modern appearance. Investors in QSR stock will note that Burger King wants to focus more on technology and digital investments. That, combined with plans for more advertising, is part of its efforts to increase sales growth and improve profitability. Burger King notes that it will spend that $400 million over a two-year period. It also has two investment plans. The first is called “Royal Reset” and will get $250 million for upgrades and remodels. The second is “Fuel the Flame” and will get $150 million for advertising and digital investments. Tom Curtis, president of Burger King North America, said the following about the investments. “We are relentlessly pursuing a better experience for our Guests.
→ Google Traductor
Bristol Myers Squibb rallies after FDA approves Sotyktu for psoriasis Morningstar
→ Google Traductor
Futures Jump As Dollar Slide Accelerates It appears that Goldman''s trading desk was right again. Just days after the vampire squid''s sellside researchers were warning that the market has not yet bottomed, the bank''s far more accurate flow traders said that " The Pain Trade Is Now Up, The CPI Doesn''t Matter At All, And The Q4 Chase Starts Early ", and on Monday morning it was all engines go in global stock markets, with US equities poised to extend their brisk rally from last week as investors braced for the final CPI before the Federal Reserve’s September decision. Futures for the S&P 500 and Nasdaq 100 both rose 0.5% each at 715 a.m. in New York, extending above their Friday session highs, putting the underlying gauges on track for a fourth day of gains, while Europe''s Stoxx 600 index climbed for a third day, and Asia was almost all green. Treasury yields dropped and the dollar retreated further as traders bet inflation is near peaking even as Fed talking heads ramped up hawkish rhetoric (it''s ok, the Fed is always 9-12 months behind the curve).
→ Google Traductor
Bristol Myers Squibb showed substantial strength in the last months compared to the market. See why I still rate BMY stock a Buy.
→ Google Traductor
Bristol Myers Squibb (NYSE:BMY) today announced new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating clinical efficacy was maintained with continuous Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. This analysis assessed patients from the pivotal POETYK PSO-1 trial who transitioned into the LTE trial. At 112 weeks
→ Google Traductor
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EADVcongress--Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data …
→ Google Traductor
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1,2 Sotyktu is not recommended for use in combination with
→ Google Traductor
BMY is down 12% from the 12-month high in late June, but has returns 13.9% for the YTD. The company maintained solid earnings growth through COVID and beyond.
→ Google Traductor
The following slide deck was published by Bristol-Myers Squibb Company in conjunction with this event.
→ Google Traductor
Pfizer with ticker code (PFE) have now 21 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 75 and 49 and has a mean target at 58.01. Now with the previous closing price of 46.13 this now indicates there is a potential upside of 25.8%. The 50 day moving average now sits at 49.88 and the 200 day MA is 51.61. The market capitalisation for the company is $264,229m. Find out more information at: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $332,277m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) Citi’s 17th Annual BioPharma Conference September 08, 2022 08:50 AM ET Company Participants Adam Lenkowsky - Head of U.S.
→ Google Traductor
Cipla''s Lenalidomide capsules are therapeutic equivalent generic version of Bristol Myers Squibb''s Revlimid (Lenalidomide) capsules The post Cipla gets US FDA nod for cancer drug appeared first on Express Pharma .
→ Google Traductor
Bristol-Myers Squibb Company (NYSE:BMY) price is hovering higher on Wednesday, September 07, jumping 1.08% above its previous close. A look at today’s price movement shows that the recent level at last check reads $68.65, with intraday deals fluctuating between $68.12 and $69.07. The company’s 5Y monthly beta was ticking 0.44 while its P/E ratio in … Bristol-Myers Squibb Company (NYSE: BMY) Jumps 1.08% In Recent Session, What Are The Points You Absolutely Need To Consider? Read More »
→ Google Traductor
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
→ Google Traductor
Cipla''s Lenalidomide Capsules are AB-rated therapeutic equivalent generic version of Bristol Myers Squibb''s (Celgene) Revlimid (Lenalidomide) Capsules.
→ Google Traductor
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
→ Google Traductor
A promising cancer drug combo from Bristol Myers Squibb is months away from being approved in the European Union to treat patients with a form of skin cancer.
→ Google Traductor
Bio-pharma Market 2022-2028 New Jersey, NJ -- ( SBWIRE ) -- 09/01/2022 -- The Latest research study released by HTF MI "Bio-pharma Market - Global Outlook and Forecast Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this Research are Pfizer, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Sanofi, Amgen, AbbVie, Merck & Co., Inc, Biogen Idec, Bayer AG, Eli Lilly and Company, Novartis AG GlaxoSmithKline Plc, Bristol-Myers Squibb Company, AstraZeneca PLC & Abbott Laboratories etc. Click here for free sample + related graphs of the report @: https://www.htfmarketreport.com/sample-report/3642289-bio-pharma-market-global-outlook-and-forecast-2021-2027 Browse market information, tables and figures extent in-depth TOC on "Bio-pharma Market - Outlook and Forecast Market by Application (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases & Others), by Product Type (, Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins & Others), Business scope, Manufacturing and Outlook – Estimate to 2027". for more information or any query mail at sales@htfmarketreport.com At last, all parts of the Bio-pharma Market - Global Outlook and Forecast Market are quantitatively also subjectively valued to think about the Global just as regional market equally.
→ Google Traductor
Michael Burry made a name for himself during the Great Recession. His bearish bet against the housing market made the contrarian investor a fortune. Alongside this fortune came fame, when the book detailing his winning trade was made into a film in 2015. When Burry makes changes to his portfolio, it makes headlines. That’s exactly what happened earlier this month, when his Scion Asset Management filed its latest 13F with the Securities and Exchange Commission (or SEC). As InvestorPlace’s Eddie Pan reported Aug. 15, the filing revealed that, as of June 30, Scion held just one stock in its portfolio : private-prison operator Geo Group (NYSE: GEO ). Much of the coverage of Burry’s latest portfolio changes has focused on why he bought GEO stock. However, what may also be of great interest is Burry’s motivation for dumping the other names that were in his portfolio as of March 31 . During the preceding quarter, Michael Burry cashed out of eleven other U.S.-listed stocks. Let’s take a look at five of his largest prior holdings, and see why he may have seen it as wise to take the money and run.
→ Google Traductor
Pfizer with ticker code (PFE) have now 21 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 75 and 49 calculating the mean target price we have 58.25. Given that the stocks previous close was at 45.85 this now indicates there is a potential upside of 27.0%. The day 50 moving average is 50.25 and the 200 day MA is 51.7. The company has a market cap of $253,847m. Visit the company website at: https://www.pfizer.com [stock_market_widget type="chart" template="basic" color="green" assets="PFE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $322,499m based on the market concensus. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women''s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
→ Google Traductor
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
→ Google Traductor
Pune, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Anticoagulants Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Anticoagulants Market Forecast to 2030, published by Market Data Centre, The Anticoagulants Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Anticoagulants Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Anticoagulants Market from 2017-to 2021 and provides extensive market forecasts from 2022 to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Anticoagulants Market.
→ Google Traductor
- ← Atrás
- 1
- 2
- 3
- …
- 15
- 16
- Siguiente →